Derek Poon

Derek Poon

Partner
Baker McKenzie

Biography

Derek Poon is a partner in Baker McKenzie's Hong Kong office and a member of the Firm's Private Equity and Mergers & Acquisitions practice groups. He is also the chair of Baker McKenzie's Asia Pacific Private Equity Group and a member of the Global Private Equity Steering Committee.

Derek has extensive experience representing private equity firms, investment banks and major corporations on a wide variety of corporate matters, including public and private mergers and acquisitions, private equity, joint ventures, real estate private equity and distressed M&A transactions. Earlier in his career, Derek spent time on client secondment with Bain Capital with the Asia Private Equity team.

Derek is recognized as a "Leading Individual" by Legal 500 Asia Pacific and as a "Up and Coming" lawyer by Chambers Greater China for Private Equity.

Practice Focus

Qualified in the US, Hong Kong, UK and Australia, Derek has worked on several significant transactions in Hong Kong, Mainland China, Japan, South Korea, Taiwan, India, Australia, ASEAN countries as well as on outbound deals into Europe and North America.

Representative Legal Matters

  • Advised EQT on its sale of Dataflow to Arcapita.

  • Advising HSBC, as financial advisor to Vinda International Holdings Limited (HKSE: 3331) in connection with the USD 3.35 billion pre-conditional voluntary conditional cash offer by RGE.

  • Advised M3IG in the sale of M3 Capital Partners to GLP Capital Partners.

  • Advised Bain Capital, AllianzX, ADQ, Vitruvian Partners, DigitalBridge, GIP, Davidson Kempner, CMC Capital, Nexus Point, New Frontier, Coatue and its portfolio companies in various investments/proposed investments in Asia.

  • Advised Prenetics on its USD 200 million joint venture with Dennis Lo named Insighta.

  • Advised CMB International in connection with PAG's mandatory general offer of Shandong Fengxiang (HKSE: 9977).

  • Advised Gaw Capital Partners and a consortium of institutional investors, including Schroder Pamfleet, on the HKD 9.845 billion acquisition of CityPlaza One office building from Swire Pacific and Swire Properties. This transaction was named “M&A Deal of the Year” in the ALB Hong Kong Law Awards 2021.

  • Advised CDPQ as lead investor on the USD 147 million growth round in Druva, a global leader in cloud data protection.

  • Advised Sino Biopharmaceutical Limited (HKSE: 1177) in various transactions including: (1) the USD 110 million acquisition of Softhale NV, a privately owned Belgian company focused on the development of products for the treatment of respiratory diseases; (2) investment alongside a consortium of investors into Treadwell Therapeutics; and (3) its strategic partnership with Boehringer Ingelheim.

  • Advised UBS AG, as financial adviser to a consortium comprising Sequoia China and Ocean Link Partners, on the proposed privatization of Zhejiang New Century Hotel Management (HKSE:1158).

  • Advised a member of an investor consortium on the proposed going private transaction of New Frontier Health (NYSE: NFH).

  • Advised an investment fund on its participation in the USD 8.7 billion take-private of 58.com (NYSE: WUBA), China's largest online classifieds marketplace, by a consortium comprising among others, Warburg Pincus, General Atlantic and Ocean Link Partners.

Admissions

  • England & Wales~United Kingdom
  • Hong Kong~China
  • New York~United States
  • New South Wales~Australia

Education

  • University of New South Wales (Bachelor of Laws)
  • University of New South Wales (Bachelor of Commerce (Accounting))
  • The College of Law (Graduate Diploma in Legal Practice)
  • University of Hong Kong (P.C.LL.)

Languages

  • Cantonese
  • English
  • Mandarin